CD274 and neoplasm: These results suggest that anti-PD-1 treatment could synergize with LIT-induced antitumor immunity by reducing the expression of PD-L1 on the surface of B16 tumor cells efficiently and decreasing the proportion of exhausting CD8+ T cells (reversing dysfunction of CTLs).